The patient who arrives in the ED with a PaCO2 of 78 mmHg, a pH of 7.28, and a SpO2 of 86% is in hypercapnic respiratory failure. Oxygen alone will fix the saturation and worsen the acidosis. CPAP alone will splint the airway but not move the CO2. BiPAP is the only home-available device class that does both — it provides the inspiratory pressure support that augments tidal volume and clears CO2, and the expiratory pressure that splints the airway and offloads work of breathing.
This guide explains what hypercapnia is, how to distinguish acute from chronic CO2 retention, why CPAP cannot substitute for BiPAP in this picture, how the BiPAP mode tree (S, S/T, T, AVAPS) maps to clinical scenarios, and what the transition from in-hospital NIV to home BiPAP looks like in the Indian healthcare system.
What hypercapnia is
Hypercapnia is an elevated partial pressure of CO2 in arterial blood. The conventional thresholds (British Thoracic Society):
- Normal PaCO2: 35-45 mmHg
- Mild hypercapnia: 45-50 mmHg
- Significant hypercapnia: > 50 mmHg
- Severe hypercapnia: > 60 mmHg
PaCO2 is set by the balance between metabolic CO2 production and alveolar minute ventilation. Production is relatively constant in stable physiology; the variable that matters is alveolar ventilation. When alveolar ventilation drops below what is needed to clear the CO2 load, PaCO2 rises. The disease conditions that drive this fall into a small number of buckets: airway obstruction limiting expiratory flow (severe COPD), restriction of chest-wall mechanics (kyphoscoliosis, OHS, fibrothorax), respiratory muscle weakness (ALS, muscular dystrophy, post-polio, diaphragm paralysis), and central respiratory drive failure (brainstem stroke, opioid overdose, congenital central hypoventilation).
The pulse oximeter cannot see CO2. A patient on supplemental oxygen with a SpO2 of 95% can have a PaCO2 of 70 mmHg and be on the verge of CO2 narcosis. Hypercapnia is a blood-gas diagnosis, not a saturation diagnosis. This is the single most important fact in this guide.
Acute vs chronic hypercapnia
The pH compensates over time. An acute rise in PaCO2 produces an acute respiratory acidosis (pH falls roughly 0.08 per 10 mmHg PaCO2 rise). Over 24-72 hours the kidneys retain bicarbonate, partially compensating, and pH partially normalises. Over weeks, the bicarbonate retention is full, and a chronic CO2-retainer can sit at PaCO2 60-65 mmHg with a pH of 7.36 indefinitely.
The discriminator on a single ABG:
- Acute hypercapnia: PaCO2 high, HCO3 normal-ish (22-26 mmol/L), pH significantly low (< 7.30 commonly).
- Chronic hypercapnia at baseline: PaCO2 high, HCO3 high (28-35 mmol/L), pH near normal (7.35-7.42).
- Acute-on-chronic exacerbation: PaCO2 even higher than chronic baseline, HCO3 high (the chronic compensation), pH low (the acute decompensation has overrun the compensation).
This distinction drives where the patient is treated. Acute or acute-on-chronic hypercapnia in the ED with pH < 7.35 needs in-hospital NIV initiation, often in a step-down or HDU bed. Chronic compensated hypercapnia in an outpatient may need home BiPAP initiation but does not need an admission. Misreading the second as the first sends well-compensated chronic CO2-retainers through unnecessary admissions; misreading the first as the second sends acute decompensations home to die.
Why CPAP alone is wrong
CPAP delivers a single continuous pressure across inspiration and expiration. It splints the upper airway open, which solves obstructive sleep apnea. It does not provide pressure support — the patient still has to do all the inspiratory work to move tidal volume against the splinting pressure.
For a patient with weak respiratory muscles, severe airway obstruction, or restrictive chest-wall disease, CPAP is at best neutral on minute ventilation and at worst increases work of breathing. CO2 clearance does not improve. Some patients on CPAP for OSA who develop progressive OHS or who have undiagnosed neuromuscular weakness will accumulate CO2 over weeks of “successful” CPAP therapy, and their pulmonologist will discover the problem only when the patient becomes encephalopathic.
BiPAP separates the two pressures. The IPAP-EPAP gap (the pressure support) is the active assist on each breath. A pressure support of 8-10 cmH2O typically increases the patient’s spontaneous tidal volume by 30-50%, which in turn increases minute ventilation, which clears CO2 (British Thoracic Society).
The decision is therefore not preference. CPAP and BiPAP treat overlapping but mechanistically different problems. CPAP for airway-collapse-driven OSA. BiPAP wherever ventilation itself is the problem.
NIV indications
The accepted home-NIV indications (British Thoracic Society):
Hypercapnic COPD post-exacerbation. A landmark trial established that COPD patients with persistent hypercapnia (PaCO2 > 53 mmHg, on optimal therapy, ≥ 2 weeks post-exacerbation) randomised to home NIV showed reduced exacerbation rate and reduced mortality at 12 months versus oxygen-only (Murphy PB et al, JAMA 2017). This is the single largest prospective signal supporting home BiPAP in the COPD population.
Obesity hypoventilation syndrome. BMI > 30, daytime PaCO2 > 45 mmHg, no other cause. CPAP works for the OSA component in many OHS patients but a substantial fraction need bilevel pressure support, often with volume assurance, to fully correct daytime hypercapnia (Masa JF et al, Pickwick trial (Lancet 2019)).
Neuromuscular disease. ALS, muscular dystrophy, post-polio, kyphoscoliosis. NIV is initiated when nocturnal hypoventilation develops (overnight oximetry showing sustained desaturation, or a daytime PaCO2 > 45 mmHg, or symptoms of nocturnal hypoventilation — morning headache, daytime sleepiness, orthopnea).
Restrictive thoracic disease. Severe kyphoscoliosis, post-thoracoplasty, fibrothorax. Mechanism similar to neuromuscular — chest-wall mechanics fail, hypoventilation develops, NIV restores adequate minute ventilation.
Post-extubation in selected ICU patients. Particularly hypercapnic COPD patients extubated to NIV-as-bridge. Reduces re-intubation rate in this population.
BiPAP mode selection: S vs S/T vs T
Modern home BiPAP units offer three core modes that differ in how the device handles patient effort and timing.
Spontaneous (S) mode. Every breath is patient-triggered. The device delivers IPAP when it detects an inspiratory effort and drops to EPAP at the end of inspiration. There is no backup rate. If the patient stops breathing for any reason, the device will not deliver a breath. Indicated for patients with reliable, intact respiratory drive — most adult OSA, most stable COPD, most OHS without significant nocturnal apnea.
Spontaneous/Timed (S/T) mode. Same patient-triggered behaviour as S mode, but with a backup rate. If the patient does not trigger a breath within the set window (e.g., > 4 seconds at a backup rate of 12), the device delivers a machine-timed breath. Indicated for any patient with unreliable respiratory drive, central apnea risk, neuromuscular disease with weak triggering effort, or significant central component to mixed disease. The standard mode for chronic hypercapnia of any cause where the underlying physiology cannot guarantee uninterrupted spontaneous breathing.
Timed (T) mode. All breaths are machine-timed. The patient is essentially passive. Used in ICU and end-stage neuromuscular settings, rarely in conventional home NIV.
The default mode for hypercapnic respiratory failure with chronic NIV-at-home indication is S/T. The backup rate is the safety margin against the failure mode the disease can produce — apnea or near-apnea during sleep.
AVAPS and TVAPS volume-target overlay
Conventional BiPAP delivers a set IPAP. The tidal volume the patient receives depends on the patient’s lung mechanics, the set IPAP-EPAP gap, and the patient’s effort. A patient whose airway resistance changes overnight (mucus, position, sleep stage) will receive a varying tidal volume.
Average Volume-Assured Pressure Support (AVAPS, Philips) and Target Volume Assured Pressure Support (TVAPS, ResMed) overlay a volume target on the bilevel framework. The clinician sets a target tidal volume; the device adjusts IPAP within a min-max window, breath by breath, to hit that volume target.
The clearest indication for AVAPS/TVAPS is OHS — the disease has variable upper-airway resistance from sleep stage to sleep stage and from position to position, and a fixed-IPAP BiPAP often delivers undertreatment in REM sleep and overtreatment in lateral non-REM. Volume targeting smooths this out and improves CO2 control. The other established indication is progressive neuromuscular disease with declining tidal-volume capacity, where volume assurance compensates for the changing physiology.
AVAPS/TVAPS-capable units cost ₹1,40,000-₹2,50,000 in the Indian market — roughly double a standard BiPAP-ST. Whether the upgrade is justified depends on the underlying disease and whether the patient has demonstrated inadequate CO2 control on conventional BiPAP-ST first.
Transition from in-hospital NIV to home NIV
A patient initiated on NIV in the ICU for acute or acute-on-chronic hypercapnic failure does not automatically transition to home NIV. The transition criteria are more selective.
Continue to home NIV if:
- The acute precipitant has resolved but persistent hypercapnia remains (PaCO2 > 50 mmHg on optimal medical therapy, ≥ 2 weeks post-resolution)
- The underlying disease is one of the established home-NIV indications (severe COPD, OHS, neuromuscular, restrictive)
- The patient tolerated NIV during the admission and adheres to a reasonable duration (typically ≥ 5 hours/night during the in-hospital trial)
- The home environment can accommodate the equipment and the family can be trained on basic operation and alarm response
Transition to oxygen-only or no support if:
- The acute precipitant has fully resolved and the hypercapnia has normalised on follow-up ABG
- The patient does not tolerate NIV at home
- Other goals-of-care considerations apply
The Indian-market specifics for this transition:
- NIV initiation in Indian ICUs is widespread in Tier-1 hospitals; less consistent in Tier-2/3. Most teaching hospitals run NIV protocols that are aligned with international standards.
- Home BiPAP-ST availability is now broad across Indian Tier-1 cities. The major brands (ResMed Lumis ST, Philips DreamStation BiPAP S/T, BMC G3 ST, Home Medix HM-BV-30 alongside several others) cover the standard indications. AVAPS/TVAPS units are less stocked outside metros and often have to be ordered.
- Sleep physician vs pulmonologist routing. Home NIV initiation outside the post-ICU window is typically a pulmonologist or sleep physician decision. Some Indian sleep labs run formal NIV-titration studies (often called “BiPAP titration”) which are more involved than a CPAP titration — the technician adjusts both pressures and the backup rate during the night against ABG or transcutaneous CO2 monitoring. The output is a written prescription specifying mode, IPAP, EPAP, backup rate, and (for AVAPS) target tidal volume.
- Dealer-side configuration depth. The dealer who installs the BiPAP must be able to enter the prescription settings on the unit. Most Tier-1 dealers can; Tier-2/3 dealers often install a unit set to a generic factory default and rely on the prescribing physician to adjust later, which is suboptimal.
Equipment selection within the BiPAP-ST class
Once the prescription is BiPAP-ST or BiPAP with volume assurance, the brand selection criteria are:
- Pressure delivery accuracy. The actual delivered IPAP at the mask versus the set IPAP. Established brands (ResMed, Philips) tend to track within ±0.5 cmH2O; some lower-cost units drift more.
- Synchrony. How well the device matches the patient’s inspiratory and expiratory transitions. Poor synchrony manifests as ineffective triggering, late cycling, and patient discomfort.
- Leak tolerance. Mask leak is constant in clinical use; the device’s ability to maintain pressure delivery despite varying leak determines whether therapy holds across the night.
- Data and remote monitoring. Modern BiPAPs report adherence, AHI residuals, leak, and pressure data to a clinician portal. This matters for long-term follow-up.
- Service depth. A BiPAP unit is more complex than a CPAP and has more failure modes. Brand service availability at the patient’s location is more important here than for simpler equipment.
The Indian field for BiPAP-ST in 2026: ResMed Lumis 150 VPAP ST and Lumis 100 VPAP S, Philips DreamStation BiPAP S/T and DreamStation 2 BiPAP, BMC G3 BPAP ST, Home Medix HM-BV-30, and several Chinese OEM imports. AVAPS/TVAPS-capable units narrow to Philips DreamStation AVAPS and ResMed Lumis 150 VPAP ST-A as the dominant choices, with thinner alternatives below.
The takeaway
Hypercapnic respiratory failure is a different problem from oxygenation failure, and BiPAP is the only home-available device class that addresses it. CPAP and oxygen alone are inadequate substitutes — they fix saturation while leaving CO2 to accumulate. The mode tree (S, S/T, AVAPS/TVAPS) maps to the underlying physiology, with S/T as the default for chronic hypercapnia at home and AVAPS as the upgrade for OHS and progressive neuromuscular disease. The transition from in-hospital NIV to home NIV is a selective decision made on persistent hypercapnia after the acute event has resolved, not an automatic continuation.
This guide is editorial opinion and general information. It is not medical advice. Consult your physician for therapy decisions, and verify all specifications with the manufacturer before purchase.